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Background: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment
options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first
agent to improve survival of patients with advanced melanoma in a randomised, controlled phase 3 trial. We used data
from an expanded access programme (EAP) at Italian centres to evaluate the clinical activity and safety profile of
ipilimumab 10 mg/kg in patients with advanced melanoma in a setting more similar to that of daily practice.
Methods: Data were collected from patients enrolled in an ipilimumab EAP across eight participating Italian centres. As
per the EAP protocol, patients had life-threatening, unresectable stage III/IV melanoma, had failed or did not tolerate
previous treatments and had no other therapeutic option available. Treatment comprised ipilimumab 10 mg/kg every
3 weeks for a total of four doses. If physicians believed patients would continue to derive benefit from ipilimumab
treatment, maintenance therapy with ipilimumab 10 mg/kg was provided every 12 weeks. Tumour responses were
assessed every 12 weeks using modified World Health Organization criteria and safety continuously monitored.
Results: Seventy-four pretreated patients with advanced melanoma were treated with ipilimumab 10 mg/kg. Of these,
9 (13.0%) had an objective response, comprising 3 patients with a complete response and 6 with a partial response.
Median overall survival was 7.0 months (95% confidence interval, 5.3–8.7) and 16.6% of patients were alive after 3 years.
Forty-five patients (60.8%) reported treatment-related adverse events of any grade, which were most commonly
low-grade pruritus, pain, fever and diarrhoea. Grade 3 or 4 treatment-related AEs were reported in 8 patients (10.8%).
Conclusions: The clinical activity and safety profile of ipilimumab 10 mg/kg in the EAP was similar to that seen in
previous clinical trials of ipilimumab in pretreated patient populations.
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Until recently, patients with unresectable stage III and
IV (advanced) melanoma faced a dismal prognosis and
had limited treatment options [1-4]. However, advances
in the understanding of cancer immunology and the mo-
lecular pathways involved in melanoma pathogenesis led
to exciting developments and new treatments with the* Correspondence: mmaiocro@gmail.com
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reproduction in any medium, provided the orpotential to provide patients with improved survival. In
2011, two new agents were approved for the treatment
of patients with advanced melanoma; ipilimumab, a
novel immunotherapy, and vemurafenib, a specific BRAF
inhibitor for patients with BRAFV600-mutation positive
melanoma. These agents have changed the treatment
landscape for this difficult to treat disease, with other
novel therapeutic approaches on the horizon [5,6].
Ipilimumab is a fully-humanised monoclonal antibody
that blocks cytotoxic T-lymphocyte-associated antigen-4,tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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T-cell activation, proliferation and infiltration into tu-
mours [7]. The antitumour activity of ipilimumab in pa-
tients with advanced melanoma has been demonstrated
in a number of phase 2 trials [8-12] and in two phase 3
trials; one as monotherapy in patients with pretreated
metastatic melanoma at a dose of 3 mg/kg, and the sec-
ond in combination with chemotherapy in patients with
previously untreated metastatic melanoma at a dose of
10 mg/kg [13,14]. Recent updates from clinical trials of
pretreated and treatment-naïve patients treated with ipi-
limumab 10 mg/kg have shown long-term clinical bene-
fit, with some patients surviving at least 5 years [15,16].
Most adverse events (AEs) to ipilimumab reported in
clinical trials are low-grade and immune-related and, in
most cases, can be managed with appropriate medical
therapy, treatment interruption or withdrawal [17-19].
Clinical trials, by virtue of design, include highly-
selected patient populations and investigative agents are
provided according to tightly-regulated protocols. The
ipilimumab Expanded Access Programme (EAP;
formerly known as the ipilimumab Compassionate Use
Programme) was initiated to provide ipilimumab to pa-
tients who were not eligible to receive ipilimumab within
clinical trials, therefore providing a real-world perspec-
tive on the efficacy, safety and general management of
ipilimumab in a setting representative of daily clinical
practice. Initially, ipilimumab was provided at a dose of
10 mg/kg; however, the protocol was later amended to
allow the use of ipilimumab 3 mg/kg, in line with the
approved European label.
Results from 27 patients treated with ipilimumab
10 mg/kg at a single centre in the EAP in Italy have pre-
viously been reported [20,21]. Here, we provide long-
term follow-up from all patients treated with ipilimumab
10 mg/kg within a participating Italian centre.
Methods
Patient population
This was a retrospective analysis of data from patients
whose physician requested compassionate use of ipilimu-
mab through the EAP. Patients older than 16 years of age
with histologically confirmed unresectable stage III and
stage IV skin, ocular or mucosal melanoma were eligible
for inclusion in the EAP. Patients must have failed sys-
temic therapy, been intolerant to ≥1 systemic therapy, or
had no other therapeutic option available to them. An
Eastern Cooperative Oncology Group (ECOG) perform-
ance status (PS) of 0, 1, or 2 was required, and an interval
of at least 28 days since treatment with chemotherapy,
biochemotherapy, surgery, radiation, or immunotherapy
was recommended. Patients with asymptomatic brain me-
tastases were allowed. Exclusion criteria included any
other systemic therapy for melanoma, concomitantautoimmune diseases or other malignancies, and known
HIV, hepatitis B, or hepatitis C infection.
Study design and data collection
Ipilimumab 10 mg/kg was administered intravenously
over 90 minutes every 3 weeks for a total of four doses
(induction phase). Eligible patients could receive main-
tenance therapy with ipilimumab 10 mg/kg every
12 weeks, if tolerated, for as long as the physician be-
lieved that benefit would be derived from treatment. Pa-
tients who progressed following either stable disease
(SD) of ≥3 months’ duration or an initial objective re-
sponse (partial [PR] or complete response [CR]) were of-
fered retreatment with the same dosing schedule used
during the induction phase.
Treatment was discontinued in cases of confirmed dis-
ease progression as determined using modified World
Health Organization (mWHO) criteria, a related AE ne-
cessitating discontinuation of ipilimumab, clinical deteri-
oration (as per protocol), withdrawal of consent, or
pregnancy.
Tumour assessments utilising helical (spiral) compu-
terised tomography scans of brain, chest, abdomen, and
pelvis, were conducted at baseline and every 12 weeks
thereafter. Clinical response was defined according to
mWHO criteria as CR, PR, SD or progressive disease
(PD). Disease control rate (DCR) was defined as the per-
centage of patients achieving CR, PR, or SD lasting at
least 24 weeks from the first dose of ipilimumab.
Safety was continuously monitored and assessed in all
patients who received ipilimumab in the EAP. AEs were
graded according to the National Cancer Institute Com-
mon Terminology Criteria for AEs, version 3.0.
Statistical analysis
Data were analysed using descriptive statistics, such as
median and range. Progression-free survival (PFS) and
overall survival (OS) were estimated using Kaplan–Meier
analysis and expressed as median values with corre-
sponding two-sided 95% confidence intervals (CIs).
Results
Patients
As part of the EAP, 74 patients with advanced melanoma
were treated with ipilimumab 10 mg/kg across eight par-
ticipating Italian centres. Baseline characteristics of these
patients are provided in Table 1. Of the 74 patients treated
with ipilimumab, 43 (58.1%) received all four induction
doses, 14 (18.9%) received three doses, 5 (6.8%) received
two doses and 12 (16.2%) received only one dose. Reasons
for discontinuation comprised disease progression (n =
13), death due to disease progression (n = 10), loss to
follow-up (n = 5), study drug toxicity (n = 2), and unknown
reasons (n = 1). The median number of doses received was
Table 1 Patient characteristics at baseline
Characteristic
Patients, N 74
Gender, n (%)
Male 46 (62.2)
Female 28 (37.8)
Age, years, median (range) 56 (23–79)
Time from diagnosis, months, median (range) 31 (5–206)
Melanoma diagnosis, n (%)
Cutaneous 57 (77.0)
Uveal 9 (12.2)
Mucosal 2 (2.7)
Unknown 6 (8.1)
Presence of brain metastases 11 (14.9)
M stage, n (%)
M0 (unresectable stage III) 2 (2.7)
M1a 16 (21.6)
M1b 2 (2.7)
M1c 53 (71.6)
Unknown 1 (1.4)
ECOG PS
0 43 (58.1)
1 29 (39.2)
2 2 (2.7)
LDH
Median (range), units/L 466 (139–4416)
>Upper limit of normal (480 units/L), n (%) 37 (50)
Number of prior therapies for metastatic disease,
median (range)
2 (1–5)
ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PS
performance status.
Table 2 Clinical response to ipilimumab 10 mg/kg
Response Responses at the
end of induction, week
12 (N = 69)* n (%)
Responses across
all treatment phases
(N = 69)* n (%)
CR 1 (1.5) 3 (4.3)
PR 5 (7.2) 6 (8.7)
SD 15 (21.7) 13 (18.9)
PD 48 (69.6) 47 (68.1)
ORR 6 (8.7) 9 (13.0)
DCR N/A 22 (31.9)
* Evaluable patients.
By definition, SD must be of at least 24 weeks duration to be included in the
disease control category.
CR complete response, DCR disease control rate (PR + CR + SD), N/A not
applicable, ORR objective response rate, PD progressive disease, PR partial
response, SD stable disease.
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maintenance treatment with ipilimumab, with a median
number of cycles of two (range: 1–13). Reasons for not re-
ceiving maintenance therapy were disease progression (n
= 30), death due to disease progression (n = 9), loss to fol-
low up (n = 5) and toxicity (n = 2; 1 patient with grade 2
diarrhoea and nausea, and 1 with grade 1 diarrhoea). As of
December 2012, 6 patients were still receiving mainten-
ance therapy. Reasons for discontinuing maintenance
therapy were disease progression (n = 14), death due to
disease progression (n = 4) and physician decision (n = 1).
Two patients with disease progression after four cycles of
maintenance therapy were retreated with ipilimumab
10 mg/kg every 3 weeks for a total of four doses; an add-
itional patient with disease progression who did not re-
ceive maintenance therapy was retreated with ipilimumab
at 3 mg/kg every 3 weeks for a total of four doses.Tumour response
Of all treated patients, 69 were evaluable for tumour re-
sponse (1 patient received three infusions but was not
assessed by CT scan, 2 patients were lost to follow-up
and 2 patients stopped treatment: 1 due to toxicity and
the other for unspecified reasons). Tumour responses
according to mWHO criteria are summarised in Table 2.
At week 12, 6 patients (8.7%) had an objective response,
including 1 patient (1.5%) with a CR and 5 (7.2%) with a
PR. Responses to ipilimumab continued to improve be-
yond week 12: across all treatment phases, a total of 9
patients (13.0%) had an objective response, including 3
patients (4.3%) with a CR and 6 (8.7%) with a PR. Of the
3 patients with an improved response, 1 patient with dis-
ease progression improved to CR, and 2 with SD im-
proved to a PR and CR, respectively. The median
duration of response has not yet been reached. In total,
22 patients (31.9%) achieved disease control. The me-
dian duration of SD was 10 months. Of the 2 patients
retreated with ipilimumab 10 mg/kg, 1 regained disease
control. The patient retreated with ipilimumab 3 mg/kg
also regained disease control, as previously described
[21]. Among the 11 patients with brain metastases at
baseline, 10 were evaluable for response. Best response
to treatment was SD in 2 (20.0%) patients and PD in 8
patients (80.0%).
Survival
With a median follow-up of 44 months, median OS was
7.0 months (95% CI, 5.3–8.7) for all patients (Figure 1)
and 4.0 months (95% CI, 2.4–5.6) for the 11 patients
with brain metastases. Excluding patients with brain me-
tastases did not impact median OS (7.0 months [95% CI,
6.2–9.8]). The 1, 2 and 3-year OS rates were 30.9%,
19.6% and 16.6%, respectively. Ten patients had long-
term survival of at least 3 years. The median lactate
dehydrohenase (LDH) level for these patients was 280
units/L, and their best response to induction therapy
100
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Figure 1 Kaplan–Meier analysis of OS among 74 patients
receiving ipilimumab 10 mg/kg at Italian centres participating
in an EAP. EAP expanded access programme, OS overall survival.
Table 3 Summary of AEs
Grade 1 Grade 2 Grade 3 Grade 4
Patients with a treatment-related
AE, n (%)
21 (28.4) 16 (21.6) 7 (9.5) 1 (1.4)
All events by maximum reported grade, n
Any 68 23 7 1
Pruritus 10 3
Diarrhoea 6 4 2
Pain 7 2 2
Fever 8 1 1
Anaemia 6 1
Rash 5 2
Nausea 6
Asthenia 5
Cough 2
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and PD in 1 patient (10.0%). With a median 13 cycles of
ipilimumab maintenance therapy, there was an evolution
in best response with 2 patients (20.0%) having a CR,
and 4 patients (40.0%) each having a PR or SD. Median
PFS was 3.0 months (95% CI, 2.3–3.7) for all patients
(Figure 2), 3.0 months (95% CI, 2.4–3.6) for the 11 pa-
tients with brain metastases and 4.0 months (95% CI,
2.9–5.0) when patients with brain metastases were ex-
cluded. As with OS, there was a plateau in PFS after
2 years. Of the 10 patients who survived more than
3 years, only 2 (20.0%) subsequently progressed (after 45
and 57 months, respectively).
Safety
Of the 74 treated patients, 45 (60.8%) reported at least 1
AE that was considered related to ipilimumab treatment.100
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Figure 2 Kaplan–Meier analysis of progression-free survival
among 74 patients receiving ipilimumab 10 mg/kg at Italian
centres participating in an EAP. EAP expanded access programme,
PFS progression-free survival.These are detailed in Table 3. The most commonly re-
ported AEs were pruritus, pain, fever and diarrhoea. Most
AEs were grade 1 or 2, with only 8 grade 3 or 4 events re-
ported (by 8 patients [10.8%] in total). Grade 3 or 4 events
comprised 2 reports each of diarrhoea and pain; and 1 re-
port each of fever, epigastric pain, elevated aspartate ami-
notransferase (AST) and pancytopenia. Time to onset of
these events was 10–73 days for the diarrhoea, increased
AST and pain, and 21 days for fever and pancytopenia. As
previously described, grade 4 pancytopenia was success-
fully managed through the discontinuation of ipilimumab
and use of supportive medications (growth factors, trans-
fusions and antibiotics), immunoglobulins and immuno-
suppressive therapy (cyclosporin) [20].
Discussion
In clinical trials of patients with advanced melanoma,
ipilimumab has been shown to provide long-termDyspnoea 1 1
Hyperthyroidism 2
Hypothyroidism 2
Infection 2
Scrotal pain 1 1
Dermatitis 1
Oedema 1
Epigastric pain 1
Herpes Zoster 1
Hypocalcemia 1
Increase in aspartate transaminase/
alanine transaminase
1
Pancytopenia 1
Other* 9
* Single AEs of grade 1 intensity: penis bleeding, cephalea, confusion, fatigue,
constipation, anorexia, inappetence and dysgeusia, flu-like syndrome, ocular
Herpes Zoster with oedema and pain.
AEs adverse events.
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[8-14,19]. To evaluate the efficacy and safety profile of
ipilimumab in a setting more representative of daily clin-
ical practice, we analysed data from 74 heavily pretreated
patients who received ipilimumab 10 mg/kg as part of
an EAP in Italy. With an estimated 44 months follow-up
across all eight participating centres, median OS was
7.0 months and one-fifth patients had long-term survival
of at least 2 years, with approximately 17% of patients
alive at 3 years. These findings are consistent with data
from clinical trials [22]. In a recent analysis, survival data
was pooled from 4846 individual patients treated with
ipilimumab within clinical studies or the US EAP. The
analysis showed a plateau in OS beginning after approxi-
mately 3 years with follow-up of up to 10 years in some
patients. Approximately 21% of patients were alive at
three years, and survival outcomes did not appear to be
impacted by prior therapy, dose or treatment regimen
[22]. These data support the durability of long-term sur-
vival with ipilimumab and suggest that if patients re-
spond to treatment and are still alive 2 or 3 years after
treatment, they have a good chance of achieving long-
term tumour control. Indeed, among the 24 patients
treated at the University Hospital of Siena in the current
analysis, 20% were alive at 4 years, further exemplifying
the consistency in long-term survival outcomes [21].
At the first tumour assessment (week 12), 9% of pa-
tients in this analysis had achieved an objective response.
This is also consistent with previous phase 2 and 3 trials
of ipilimumab monotherapy in pretreated populations,
with rates ranging from 4–11% with ipilimumab 3 mg/
kg and 6–11% with ipilimumab 10 mg/kg [9,12,13].
In previous phase 2 clinical trials of pretreated patients
who received ipilimumab 10 mg/kg, median OS has
been shown to be approximately 10 months [9,12]. As
expected, the median OS reported in this analysis is
shorter. Patients had a particularly poor prognosis and
in most cases had failed to respond to one or more prior
treatments for metastatic disease. Their disease was
therefore very advanced. Indeed, most patients (72%)
had M1c disease at the time of enrolment. Previous
studies have highlighted poor PS, presence of visceral
disease, brain metastases, elevated LDH and disease M-
stage as statistically significant prognostic factors of poor
OS [2,23]. Interestingly, in this analysis, LDH at baseline
was lower among patients who survived more than
3 years than for all treated patients: median 280 units/L
(range: 59–913) vs 466 units/L (range: 139–4416). Con-
sidering the median OS, tumour responses, and 3-year
survival rate of patients analysed here, the efficacy of ipi-
limumab in a real-world setting appears consistent with
that observed in selected clinical trial populations.
Beyond week 12, the percentage of patients experien-
cing an objective response increased. This apparentevolution in responses may reflect the indirect, immune-
mediated mechanism of action of ipilimumab. Because it
can take time to build an immune response against a
tumour, clinically measurable antitumour effects may
occur over weeks to months and can be observed after
the appearance of new lesions or an initial increase in
tumour volume, or in the form of a delayed, slow, steady
decline in total tumour volume [14,24,25]. In most cases,
clinical benefit with ipilimumab comprised durable SD,
which is often the predominant response of patients re-
ceiving ipilimumab. In clinical trials, survival outcomes
among patients with SD are similar to those of patients
with an objective response to ipilimumab [26], suggest-
ing that SD is a meaningful clinical outcome for patients
treated with this agent. This observation that most pa-
tients seem to obtain a state of tumour control rather
than one of complete tumour eradication gives credence
to the concept that ‘clinical cure’ or long-term cancer
containment is possible, and requires induction of an
antitumour immune response [27].
The AE profile seen in patients receiving ipilimumab
in the EAP was consistent with that reported in previous
clinical trials of ipilimumab 10 mg/kg, with most events
being dermatological or gastrointestinal in nature
[9,11,12]. Among 155 patients treated with ipilimumab
10 mg/kg in a phase 2 trial, 84% of patients had
treatment-related AEs of any grade, with one treatment-
related death resulting from liver failure [9]. In our ana-
lysis, 61% of patients had treatment-related AEs of any
grade and there were no treatment-related deaths. Rates
of grade ≥3 AEs appeared similar to those seen in previ-
ous clinical trials of ipilimumab 3 mg/kg, but were lower
than has been observed in clinical trials of ipilimumab
10 mg/kg [8,9,11-13]. In a trial of ipilimumab 0.3, 3 and
10 mg/kg in pretreated patients with advanced melan-
oma, the rate and severity of AEs increased with increas-
ing dose; therefore the lack of high-grade events in this
analysis is perhaps surprising, although the retrospective
nature of this analysis may have influenced the number
of AEs reported. Prompt recognition of symptoms and
appropriate management are essential to minimise life-
threatening complications from ipilimumab. A decrease
in the percentage of patients requiring intervention for
bowel perforation from 0.9% to 0.5%, for example, was
thought to be due to the introduction of management
guidelines established over the course of ipilimumab’s
clinical development [28]. It is possible, therefore, that
an increased awareness of the specific AEs associated
with ipilimumab, together with the implementation and
consistent use of established treatment algorithms, may
have contributed to the safety profile observed in this
analysis. The availability of these treatment algorithms
also means that, after thorough education on the appro-
priate management methods, ipilimumab 10 mg/kg can
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tending its use beyond specialised treatment centres.
Conclusions
Results from this analysis of heavily pretreated patients
with advanced melanoma who received ipilimumab
10 mg/kg as part of an EAP in Italy suggest that the clin-
ical activity and safety profile of ipilimumab in a real-
world setting is similar to that observed in clinical trials.
Importantly, long-term survival benefits were observed in
patients who had a particularly poor prognosis and had
failed to benefit from prior therapy, with some patients
surviving at least 3 years from the start of ipilimumab
treatment. Although further studies are needed to estab-
lish which dose of ipilimumab (3 or 10 mg/kg) will provide
patients with the most appropriate risk to benefit ratio,
this analysis shows that in the daily-clinical setting, ipili-
mumab 10 mg/kg has clinical activity in patients with ad-
vanced melanoma with manageable side effects.
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